The Chines biopharmaceutical contract manufacturing market is projected to grow at an annualized rate of ~13%, till 2030
Roots Analysis has done a detailedstudy on ChinaBiopharmaceutical Contract Manufacturing Market, 2020-2030, covering keyaspects of the industry’s evolution and identifying potential future growthopportunities.
To order this 250+page report, which features 100+ figures and 120+ tables, please visit this link
Key Market Insights
§ Over 35 CMOs / CDMOsin China claim to offer a variety of services related to development and manufacturingof a wide range of biotherapeutic products
§ Several playersprovide one-stop solutions and are capable of operating at various scales; thelandscape includes a mix of both established players and new entrants
§ In order to cater tothe evolving needs of clients / sponsors, CMOs have established facilitiesacross different regions of China; Eastern China, with the maximum number ofsites, has emerged as a manufacturing hub
§ With over 80 dealsinked in past five years, there has been a surge in the partnership activitywithin this domain; majority of these collaborations were signed for thedevelopment and manufacturing of antibody-based products
§ Big pharma players have also made significant investments in thisregion, including establishing new facilities, expanding existing R&Dcenters and growing manufacturing facilities, focused on biotherapeutics
§ We expect globalbiopharmaceutical developers to continue to outsource their manufacturingoperations to China in the long term; we anticipate the CMO industry in theregion to grow at an annualized rate of ~13%, till 2030
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
1.2. Overview of Biopharmaceuticals
3.3. Manufacturingof Biopharmaceuticals
3.3.1. Types ofExpression Systems Used
3.3.1.1. BacterialExpression Systems
3.3.1.2. YeastExpression Systems
3.3.1.3. InsectExpression Systems
3.3.1.4. PlantExpression Systems
3.3.1.5. MammalianExpression Systems
3.3.1.6. FungalExpression Systems
3.3.2. ProcessingSteps
3.3.2.1. UpstreamProcessing
3.3.2.2. DownstreamProcessing
3.4. Overview ofContract Manufacturing
3.4.1. ContractManufacturing Scenario in China
3.5. Need forOutsourcing in the Biopharmaceutical Industry
3.5.1. BiopharmaceuticalOutsourcing in China: Regulatory Scenario
3.6. CommonlyOutsourced Operations in the Biopharmaceutical Industry
3.7. BasicGuidelines for Selecting a CMO Partner
3.8. Advantagesof Outsourcing Manufacturing Services
3.8.1. Benefits ofEngaging Chinese Contract Service Providers
3.9. Risks andChallenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associatedwith Engaging Chinese Contract Service Providers
3.10. FuturePerspective
4. CASE STUDY:COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. ChapterOverview
4.2. SmallMolecule and Large Molecule Drugs / Therapies
4.2.1. Comparisonof Key Characteristics
4.2.2. Comparisonof Manufacturing Processes
4.2.3. Comparisonof Key Manufacturing-Related Challenges
5. COMPETITIVELANDSCAPE
5.1. ChapterOverview
5.2. ChineseBiopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis byYear of Establishment
5.2.2. Analysis byCompany Size
5.2.3. Analysis byScale of Operation
5.2.4. Analysis byLocation of Headquarters
5.2.5. Analysis byLocation of Manufacturing Facilities
5.2.6. Analysis byType of Product
5.2.7. Analysis byTypes of Services Offered
5.2.8. Analysis byType of Biologic
5.2.9. Analysis byExpression System Used
5.2.10. Analysis byType of Bioreactor Used
5.2.11. Analysis byMode of Operation of Bioreactor
5.2.12. Analysis byPackaging Form Used
5.2.13. Analysis byRegulatory Accreditations / Certifications
6. COMPANYPROFILES
6.1 ChapterOverview
6.2 ChemPartnerBiologics
6.2.1. CompanyOverview
6.2.2. ServicePortfolio
6.2.3. ManufacturingFacilities and Capabilities
6.2.4. RecentDevelopments and Future Outlook
6.3. JHL Biotech
6.3.1. CompanyOverview
6.3.2. ServicePortfolio
6.3.3. ManufacturingFacilities and Capabilities
6.3.4. RecentDevelopments and Future Outlook
6.4. JOINNBiologics
6.4.1. CompanyOverview
6.4.2. ServicePortfolio
6.4.3. ManufacturingFacilities and Capabilities
6.4.4. RecentDevelopments and Future Outlook
6.5 MabPlex
6.5.1. CompanyOverview
6.5.2. ServicePortfolio
6.5.3. ManufacturingFacilities and Capabilities
6.5.4. RecentDevelopments and Future Outlook
6.6. MycenaxBiotech
6.6.1. CompanyOverview
6.6.2. ServicePortfolio
6.6.3. ManufacturingFacilities and Capabilities
6.6.4. RecentDevelopments and Future Outlook
6.7. WuXi AppTec
6.7.1. CompanyOverview
6.7.2. Financial Information
6.7.3. ServicePortfolio
6.7.4. ManufacturingFacilities and Capabilities
6.7.5. RecentDevelopments and Future Outlook
7. PARTNERSHIPS
7.1 ChapterOverview
7.2. PartnershipModels
7.3. ChineseBiopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis byYear of Partnership
7.3.2. Analysis by Typeof Partnership
7.3.3. Analysis byScale of Operation
7.3.4. Analysis byType of Biologic
7.3.5. Analysis byFocus Area
7.3.6. Analysis byTherapeutic Area
7.3.7. Most ActivePlayers: Analysis by Number of Partnerships
7.3.8. GeographicalAnalysis
7.3.9. GeographicalDistribution by Number of Partnerships
7.3.10. Intercontinentaland Intracontinental Agreements
8. RECENTEXPANSIONS
8.1. ChapterOverview
8.2. ChineseBiopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis byYear of Expansion
8.2.2. Analysis byType of Expansion
8.2.3. Analysis byScale of Operation
8.2.4. Analysis byType of Biologic
8.2.5. Analysis byLocation of Expansion Project
8.2.6. Analysis byCapacity of Expanded Facility
8.2.7. Most ActivePlayers: Analysis by Number of Expansions
8.2.8. Analysis byRegion
9. CLINICALTRIAL ANALYSIS
9.1. ChapterOverview
9.2. Scope andMethodology
9.3 ClinicalTrial Analysis: Biologic Drugs
9.3.1. Analysis byTrial Registration Year
9.3.2. Analysis byTrial Phase
9.3.3. Analysis byTrial Status
9.3.4. GeographicalAnalysis by Number of Clinical Trials
9.3.5. GeographicalAnalysis by Enrolled Patient Population
9.3.6. Analysis ofEnrolled Patient Population by Trial Registration Year
9.3.7. Analysis ofEnrolled Patient Population by Trial Phase
9.3.8. Analysis byType of Sponsor / Collaborator
9.3.9. Most ActivePlayers: Analysis by Number of Registered Trials
9.3.10. Analysis byClinical Trial Center
10. REGIONALCAPABILITY ANALYSIS
10.1. ChapterOverview
10.2. Assumptionsand Key Parameters
10.3. OverallLandscape of Chinese Biopharmaceutical Contract Manufacturers
10.4. RegionalCapability Analysis: Biopharmaceuticals Contract Manufacturers in NorthernChina
10.5. RegionalCapability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
10.6. RegionalCapability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
10.7. RegionalCapability Analysis: Biopharmaceuticals Contract Manufacturers in SouthernChina
11. CAPACITYANALYSIS
11.1. ChapterOverview
11.2. Assumptionsand Methodology
11.3. ChineseBiopharmaceutical Contract Manufactures: Installed Capacity
11.3.1. Analysis byCompany Size
11.3.2. Analysis byScale of Operation
11.3.3. Analysis byExpression System Used
11.3.4. Analysis byLocation of Manufacturing Facility
11.3.5. Analysis by CompanySize and Location of Manufacturing Facility
11.3.6. Analysis by CompanySize and Location of Manufacturing Facility
11.4. ConcludingRemarks
12. BIG PHARMA BIOPHARMACEUTICALMANUFACTURING INITIATIVES IN CHINA
12.1. ChapterOverview
12.2. List ofBiopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Playersin China
12.2.1. Analysis byNumber of Initiatives
12.2.2. Analysis byYear of Initiative
12.2.3. Analysis by Companyand Year of Initiative
12.2.4. Analysis byType of Initiative
12.2.5. Analysis by Typeof Biologic
12.3. CompetitiveBenchmarking of Big Pharmaceutical Players
12.3.1. Harvey BallAnalysis: Big Pharma Investment Summary
12.3.2. GeographicalAnalysis by Investment Made
13. MAKE VERSUSBUY DECISION MAKING FRAMEWORK
13.1. ChapterOverview
13.2. Assumptionsand Key Parameters
13.3. ChinesBiopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.4. Conclusion
14. MARKETSIZING AND OPPORTUNITY ANALYSIS
14.1. ChapterOverview
14.2. KeyAssumptions and Forecast Methodology
14.3. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030
14.3.1. BiopharmaceuticalContract Manufacturing Market in China for APIs, 2020-2030
14.3.2. BiopharmaceuticalContract Manufacturing Market in China for FDFs, 2020-2030
14.4. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Distribution by ExpressionSystem Used
14.4.1. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems
14.4.2. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Microbial Systems
14.4.3. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Other ExpressionSystems
14.5. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Distribution by Scale ofOperation
14.5.1. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Preclinical /Clinical Scale Operations
14.5.2. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of CommercialOperations
14.6. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Distribution by Size ofManufacturers
14.6.1. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Small Companies
14.6.2. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies
14.6.3. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Large and VeryLarge Companies
14.7. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Distribution by Type ofBiologic
14.7.1. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Antibodies
14.7.2. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Vaccines
14.7.3. BiopharmaceuticalContract Manufacturing Market in China, 2020-2030: Share of Other Biologics
15. COVID-19Impact on China Biopharmaceutical CMO Market
15.1. ChapterOverview
15.2. Evaluationof Impact of COVID-19 Outbreak
15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. WuXi AppTec
15.2.1.2. Boehringer Ingelheim
15.2.1.3. GE Healthcare
15.2.1.4. Lonza
15.2.1.5. AmbioPharm
15.2.2. Impact ofChina Biopharmaceutical Contract Manufacturing Market
15.3. KeyStrategies to Adopt: A Bird’s Eye View
15.3.1. ImmediateSteps
15.3.2. Short /Long-Term Steps
16. SWOTANALYSIS
16.1. ChapterOverview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparisonof SWOT Factors
16.7. ConcludingRemarks
17. FUTURE OFTHE CHINA BIOPHARMACEUTICAL CMO MARKET
17.1. ChapterOverview
17.2. OutsourcingActivities Anticipated to Increase in Future
17.3. Shift fromOne-time Contracts to Strategic Partnerships
17.4. Adoption ofInnovative Technologies
17.4.1. Single Use Bioreactors
17.4.2. Novel Bioprocessing Techniques
17.4.3. Bioprocess Automation
17.5. Growing Popularityof the Quality by Design Principle in Bioprocessing
17.6. IncreasingFocus on Niche Therapeutic Areas
17.7. BiosimilarsMarket to Contribute to Contract Service Revenues
17.8. Capabilityand Facility Expansions to Establish One Stop Shop Expertise
17.9. Increase inFinancial In-flow and Outsourcing Budgets
17.10. ChallengesFaced by Sponsors and Service Providers
17.10.1. Concerns Associated with Single Use Systems
17.10.2. Issues Related to Capacity Fluctuations
17.11. ConcludingRemarks
18. INTERVIEW /SURVEY TRANSCRIPT(S)
19. APPENDIX 1:TABULATED DATA
20. APPENDIX 2:LIST OF COMPANIES AND ORGANISTIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
